<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK signaling </plain></SENT>
<SENT sid="1" pm="."><plain>However, mutant KRAS has the capacity to directly activate ERK and PI3K signaling, and this is thought to underlie the resistance of KRAS mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> to RTK inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we have elucidated the molecular regulation of both the PI3K/AKT and MEK/ERK signaling pathways in KRAS mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells and identified combination therapies that lead to robust <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>KRAS knockdown using shRNA suppressed ERK signaling in <z:hpo ids='HP_0000001'>all</z:hpo> of the human KRAS mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines examined </plain></SENT>
<SENT sid="4" pm="."><plain>However, no decrease, and actually a modest increase, in AKT phosphorylation was often seen </plain></SENT>
<SENT sid="5" pm="."><plain>By performing PI3K immunoprecipitations, we determined that RTKs, often IGF-IR, regulated PI3K signaling in the KRAS mutant cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>This conclusion was also supported by the observation that specific RTK inhibition led to marked suppression of PI3K signaling and biochemical assessment of patient specimens </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, combination of RTK and MEK inhibitors led to concomitant inhibition of PI3K and MEK signaling, marked growth suppression, and robust <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of human KRAS mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines in vitro and upon xenografting in mice </plain></SENT>
<SENT sid="8" pm="."><plain>These findings provide a framework for utilizing RTK inhibitors in the treatment of KRAS mutant <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
</text></document>